Patent Assignment
Reel/Frame 075494/0030
Release of Security Interest
Recorded: 2026-04-27
Pages: 107
Assignor
WILMINGTON TRUST, NATIONAL ASSOCIATION
Executed: 2026-04-27
Assignee
AMICUS THERAPEUTICS, INC.
3675 MARKET STREET, PHILADELPHIA, PENNSYLVANIA, 19104
Covered Properties
(207)
Methods for Treatment of Fabry Disease
Application:
17/665,969 →
Publication:
US US20220160690A1
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Application:
17/079,859 →
Publication:
US US20250082621A9
Treatment of Fabry Disease in Ert-NaïVe and Ert-Experienced Patientn
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Application:
17/346,994 →
Publication:
US US20220031681A1
Treatment Of Fabry Disease In ERT-Naïve And ERT-Experienced Patients
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens For The Treatment Of Fabry Disease
Application:
16/806,404 →
Publication:
US US20200268890A1
Dosing Regimens For The Treatment Of Fabry Disease
Application:
18/222,745 →
Publication:
US US20240115708A1
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Application:
62/444,578 →
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Application:
17/838,741 →
Publication:
US US20230158123A1
Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
Application:
16/642,620 →
Publication:
US US20200222377A1
Methods of Enhancing and/or Stabilizing Cardiac Function in Patients with Fabry Disease
Application:
62/550,984 →
Methods Of Treating Fabry Patients Having Renal Impairment
Application:
62/626,953 →
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Treatment Of Patients With Classic Fabry Disease
Application:
16/967,824 →
Publication:
US US20210038579A1
Treatment Of Patients With Classic Fabry Disease
Application:
62/626,992 →
Methods Of Treating Fabry Disease In Pregnant Patients
Application:
62/626,955 →
Use Of Migalastat For Treating Fabry Disease In Pregnant Patients
Application:
17/838,820 →
Publication:
US US20220387462A1
Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
62/719,962 →
Use of Migalostat in Reducing the Risk of Cerebrovascular Event in Patients with Fabry Disease
Application:
17/424,979 →
Publication:
US US20220087993A1
Methods Of Treating Fabry Disease In Patients Having Renal Impairment
Application:
17/618,277 →
Publication:
US US20220313670A1
Methods Of Treating Fabry Disease In Patients Having Renal Impairment
Application:
62/859,904 →
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Methods Of Treating Fabry Disease
Application:
17/172,846 →
Publication:
US US20210251972A1
Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene
Application:
17/909,450 →
Publication:
US US20230136297A1
Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same
Methods of Treating Fabry Disease
Application:
63/220,816 →
Methods of Improving the Pharmacokinetics of Migalastat
Application:
18/315,928 →
Publication:
US US20240197706A1
Methods of Improving the Pharmacokinetics of Migalastat
Application:
63/432,235 →
Dosing Regimens for the Treatment of Pompe Disease
Application:
14/398,210 →
Publication:
US US20150086530A1
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates
Application:
18/111,321 →
Publication:
US US20230203465A1
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Method For Selection Of High M6P Recombinant Proteins
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Recombinant Human Acid Alpha-Glucosidase
Recombinant Human Acid Alpha-Glucosidase
Application:
62/564,083 →
Recombinant Human Acid Alpha-Glucosidase
Application:
62/567,334 →
Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe Disease
Application:
62/506,561 →
Method for Selection of High M6P Recombinant Proteins
Application:
62/506,569 →
Recombinant Human Acid Alpha-Glucosidase
Application:
62/618,021 →
Recombinant Human Acid Alpha-Glucosidase
Application:
62/624,638 →
Recombinant Human Acid Alpha-Glucosidase
Application:
62/660,758 →
Recombinant Human Acid Alpha-Glucosidase and Uses Thereof
Application:
18/276,954 →
Publication:
US US20240197839A1
Methods for Treating Pompe Disease
Application:
63/399,498 →
Methods for Treating Pompe Disease
Application:
63/399,491 →
Methods for Treating Pompe Disease
Application:
63/404,475 →
Methods for Treating Pompe Disease
Application:
63/414,897 →
Methods for Treating Pompe Disease
Application:
63/428,970 →
Methods for Treating Pompe Disease
Application:
63/431,920 →
Methods for Treating Pompe Disease
Application:
63/434,791 →
Methods for Treating Pompe Disease
Application:
63/447,222 →
Methods for Treating Late Onset Pompe Disease in Pediatric Patients
Application:
63/429,966 →
Methods for Treating Infantile-Onset Pompe Disease in Pediatric Patients
Application:
63/429,969 →
Methods for Treating Infantile-Onset Pompe Disease in Pediatric Patients
Application:
63/449,810 →
Gene Therapy Constructs for the Treatment of Pompe Disease
Application:
63/438,960 →
Drug Package
Patent:
1,082,532 →
Application:
29/801,766 →
CDKL5 Expression Variants and CDKL5 Fusion Proteins
Application:
16/768,511 →
Publication:
US US20200299654A1
CDKL5 Fusion Proteins
Application:
62/592,944 →
Gene Therapy Constructs and Methods of Use
Application:
18/053,160 →
Publication:
US US20230233711A1
Disulfide Bond Stabilized Polypeptide Compositions and Methods of Use
Recombinant CDKL5 Proteins, Gene Therapy and Production Methods
Application:
17/773,416 →
Publication:
US US20230043046A1
Method For Capturing And Purification Of Biologics
Application:
17/640,456 →
Publication:
US US20230220320A1
Variant IGF2 Constructs
Application:
17/767,803 →
Publication:
US US20240091321A1
Vesicle Targeting Proteins And Uses Of Same
Application:
18/040,866 →
Publication:
US US20240043494A1
TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
Application:
16/314,145 →
Publication:
US US20210268072A1
TATk-CDKL5 Fusion Proteins, Compositions, Formulations, And Use Thereof
Application:
62/381,886 →
Neurotensin Variants and Tagged Proteins Comprising Neurotensin or Sortilin Propeptide
Application:
63/217,500 →
Adeno-Associated Virus Delivery of CLN3 Polynucleotide
Application:
63/248,756 →
Biomarkers For Lysosomal Storage Diseases
Application:
63/253,749 →
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders
Application:
16/049,203 →
Publication:
US US20180334432A1
Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage Disorders
Assays for Diagnosing and Evaluating Treatment Options for Fabry Disease
Methods For Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Methods for Treatment of Fabry Disease
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Patent:
48,608 →
Application:
16/222,305 →
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method to Predict Response to Pharmacological Chaperone Treatment of Diseases
Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene
Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Methods Of Treating Fabry Patients Having Renal Impairment
Use of Migalastat for Treating Fabry Disease in Pregnant Patients
Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same
Highly Purified Batches of Pharmaceutical Grade 1-Deoxygalactonojirimycin Compounds
Drug Package
Patent:
843,850 →
Application:
29/585,388 →
Drug Package
Patent:
877,625 →
Application:
29/605,763 →
Drug Package
Patent:
867,162 →
Application:
29/684,830 →
Method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives
Method for the Treatment of Pompe Disease Using 1-Deoxynojirimycin Derivatives
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Highly Potent Acid Alpha-Glucosidase with Enhanced Carbohydrates
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Augmented Acid Alpha-Glucosidase for the Treatment of Pompe Disease
Method for Selection of High M6P Recombinant Proteins
Method for Selection of High M6P Recombinant Proteins
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Formulations Comprising Recombinant Acid Alpha-Glucosidase
Gene Therapy Constructs and Methods of Use
Gene Therapy Constructs and Methods of Use
Disulfide Bond Stabilized Polypeptide Compositions and Methods of Use
Treatment of CDKL5 Disorders with GSK3B Inhibitor Tideglusib
TATk-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
TATk-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF
Tatk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
TATk-CDKL5 Fusion Proteins, Compositions, Formulations, And Use Thereof
Pharmacological Chaperones for Treating Obesity
Pharmacological Chaperones for Treating Obesity
Tartrate Salt of Isofagomine and Methods of Use
Periodic Acid-Schiff Staining with Detection in the Infrared Range
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
Mouse Model for Pompe Disease and Methods of Use Thereof
Methods for Preventing and/or Treating Lysosomal Storage Disorders
Methods for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Multiple Compartment Dosing Model
Method for Treating Alzheimer's Disease Using Pharmacological Chaperones To Increase The Activity of Gangliosidases
Method for Treating Cerebral Amyloid Angiopathy Using Pharmacological Chaperones to Increase the Activity of Gangliosidases
Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System
Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System
Compounds and Methods for Treating or Preventing Disease Conditions Associated with Alpha-1-Antitrypsin
Compounds and Methods for Treating or Preventing Disease Conditions Associated with Alpha-1-Antitrypsin
Novel Compositions For Preventing And/Or Treating Degenerative Disorders Of The Central Nervous System And/Or Lysosomal Storage Disorders
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Novel Compounds For Preventing And/Or Treating Lysosomal Storage Disorders And/Or Degenerative Disorders Of The Central Nervous System
Alpha-Galactosidase a and 1-Deoxygalactonojirimycin Co-Formulation
Alpha-Galactosidase A And 1-Deoxygalactonojirimycin Co-Formulation
Alpha-Galactosidase A And 1-Deoxygalactonojirimycin Co-Formulation For The Treatment of Fabry Disease
Urinary Triaosylceramide (GB3) as a Marker of Cardiac Disease
Stable Parenteral Dnj Compositions
Stable Parenteral DNJ Compositions
Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses
Novel Signal Sequences to Improve Protein Expressions and Secretion of Recombinant Enzymes and Other Proteins
Methods for Coupling Targeting Peptides Onto Recombinant Lysosomal Enzymes for Improved Treatments of Lysosomal Storage Diseases
Methods for Coupling Targeting Peptides Onto Recombinant Lysosomal Enzymes for Improved Treatments of Lysosomal Storage Diseases
Chemical Crosslinkers
Chemical Crosslinkers
Sugar Derivatives Comprising Sulfur-Containing Moieties and Methods of Making Same and Methods of Using the Same for the Treatment of Mps Iiic
Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy
Novel Compounds And Methods For The Treatment Of Alzheimer's Disease And/Or Cerebral Amyloid Angiopathy
Compounds and Methods for the Treatment of Alzheimer's Disease and/or Cerebral Amyloid Angiopathy
Regimens For Treating And Preventing Lysosomal Disorders And Degenerative Disorders Of The Central Nervous System
Related Assignments
(10)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Interest
May 11, 2020
From: AMICUS THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 052625/0916 →
Omnibus Confirmation of Assignment Agreement
May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
Security Interest
Jul 30, 2020
From: AMICUS THERAPEUTICS, INC.
To: HAYFIN SERVICES LLP, AS AGENT
Reel/Frame 053365/0342 →
Release of Security Interest
Jul 30, 2020
From: BPCR LIMITED PARTNERSHIP
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 053360/0659 →
Assignment of Assignor's Interest
May 10, 2022
From: GOTSCHALL, RUSSELL
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 059879/0309 →
Assignment of Assignor's Interest
Aug 5, 2022
From: CASTELLI, JEFF; BENJAMIN, ELFRIDA
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 061099/0803 →
Release of Security Interest
Oct 6, 2023
From: HAYFIN SERVICES LLP
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 065164/0945 →
Security Interest
Oct 6, 2023
From: AMICUS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 065177/0196 →
Assignment of Assignor's Interest
Jul 11, 2024
From: CASTELLI, JEFF
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 067959/0418 →
Security Interest
Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →